STOCK TITAN

Lixte Biotechnology Holdings (LIXT) Financials

LIXT NASDAQ

Ticker history: LIXT became NMAD (Nomad Power Solutions, Inc.) on .

Trailing 12 months to March 31, 2026
Revenue Not reported for the trailing 12 months
Net Income -$7.4M n/m YoY
EPS (Diluted) -$1.26 FY2025 annual
Operating Cash Flow -$4.3M n/m YoY
Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LIXT SEC filings page.

This page shows Lixte Biotechnology Holdings, Inc. (LIXT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LIXT FY2025

The figures describe a loss-making, equity-funded operation whose balance sheet expanded sharply while core operations still consumed cash.

In FY2025, the company paired a financing inflow of $10.3M with operating cash flow of -$3.1M; funding, rather than operations, supplied the cash that supported its balance-sheet expansion.

Liabilities fell to 13.9% of assets in FY2025 from 27.8% in FY2024, indicating a less debt-heavy balance-sheet mix. The current ratio rose to 3.9x from 3.6x, showing more current-asset coverage per unit of short-term obligation.

The company recorded a net loss of $6.1M alongside operating cash flow of -$3.1M; the smaller cash outflow means accounting losses exceeded immediate cash consumption, possibly reflecting noncash items or balance-sheet movements. Reported liquidity represented 20 months of the latest annual operating outflow, separating short-term coverage from operating self-funding.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Lixte Biotechnology Holdings, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
3/6

Lixte Biotechnology Holdings, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

Lixte Biotechnology Holdings, Inc. reported a net loss of $6.1M while operations used $3.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Lixte Biotechnology Holdings, Inc. reported an operating loss of $5.1M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income
-$2.0M
YoYn/m
QoQn/m

Lixte Biotechnology Holdings, Inc. reported a net loss of $2.0M in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.18

Lixte Biotechnology Holdings, Inc. earned -$0.18 per diluted share (EPS) in Q1 2026.

Revenue

Not reported for Q1 2026.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt
$3.3M
YoY+134.8%
QoQ-36.3%
5Y CAGR-15.9%
10Y CAGR+41.7%

Lixte Biotechnology Holdings, Inc. held $3.3M in cash as of Q1 2026; no long-term debt figure is on record for that period.

Shares Outstanding
12M
QoQ+32.2%

Lixte Biotechnology Holdings, Inc. had 12M shares outstanding in Q1 2026. Against the prior quarter it is up 32.2%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity
-25.0%
YoY+36.2pp
QoQ+2.0pp

Lixte Biotechnology Holdings, Inc.'s quarterly ROE was -25.0% in Q1 2026: one quarter's net income over shareholder equity, not annualized. This is up 36.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.0 percentage points.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Net Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending
$333K
YoY+264.5%
QoQ+539.7%

Lixte Biotechnology Holdings, Inc. invested $333K in research and development in Q1 2026. This represents an increase of 264.5% from the same quarter a year earlier. Against the prior quarter it is up 539.7%.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

LIXT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LIXT quarterly income statement
MetricQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
R&D Expenses$333K+264.5%$52K+49.6%$51K-86.0%$61K-71.2%$91K-23.2%$35K$362K+173.0%$211K-50.7%
SG&A Expenses$1.7M+168.7%$1.8M+206.3%$1.8M+181.6%$714K-10.6%$615K-27.4%$579K$622K+74.6%$798K+52.8%
Operating Income-$2.0Mn/m-$1.8Mn/m-$1.8Mn/m-$775Kn/m-$707Kn/m-$613K-$983Kn/m-$1.0Mn/m
Interest Expense$3K-1.2%N/A$457-56.4%$2K-56.4%$3K-56.4%N/A$1K+276.0%$4K+113.2%
Net Income-$2.0Mn/m-$2.6Mn/m-$2.0Mn/m-$776Kn/m-$710Kn/m-$618K-$986Kn/m-$1.0Mn/m
EPS (Basic)-$0.18N/A-$0.33-$0.29-$0.29n/mN/A-$0.44n/m-$0.45n/m
EPS (Diluted)-$0.18N/A-$0.33-$0.29-$0.29n/mN/A-$0.44n/m-$0.45n/m
Diluted Shares (Avg)11MN/A6M3M2M+9.9%N/A2M+8.4%2M+35.0%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.

LIXT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LIXT quarterly balance sheet
MetricQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Total Assets$10.9M+617.5%$12.7M+1011.6%$5.4M+220.4%$1.2M-55.4%$1.5M-57.8%$1.1M-73.4%$1.7M-67.6%$2.7M-13.8%
Current Assets$3.4M$5.2M+352.1%$5.4M+221.7%$990K-62.9%N/A$1.1M-73.4%$1.7M-67.7%$2.7M-13.8%
Cash & Equivalents$3.3M+134.8%$5.1M+391.5%$2.9M+76.3%$887K-65.8%$1.4M-59.4%$1.0M-75.3%$1.6M-67.9%$2.6M-10.9%
Total Liabilities$1.7M+375.0%$1.8M+456.8%$521K+58.5%$537K+27.4%$355K-23.3%$318K+1.4%$329K+5.5%$421K+4.7%
Current Liabilities$1.2M+245.0%$1.3M+318.8%$521K+58.5%$537K+27.4%$355K-23.3%$318K+1.4%$329K+5.5%$421K+4.7%
Non-Current Liabilities$462Kn/m$439Kn/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Equity$7.9M+585.4%$9.7M+1068.3%$4.9M+259.4%$651K-71.0%$1.2M-62.9%$827K-79.3%$1.4M-72.2%$2.2M-16.6%
Retained Earnings-$60.0Mn/m-$58.1Mn/m-$55.5Mn/m-$53.6Mn/m-$52.8Mn/m-$52.1Mn/m-$51.4Mn/m-$50.5Mn/m

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.

LIXT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LIXT quarterly cash flow statement
MetricQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Operating Cash Flow-$1.8Mn/m-$1.1Mn/m-$927Kn/m-$487Kn/m-$568Kn/m-$599Kn/m-$958Kn/m-$819Kn/m
Stock-Based Compensation$82K-17.6%N/A$777K+627.0%$268K+105.1%$100K-3.1%N/A$107K-4.7%$131K-53.3%
Investing Cash Flow-$25K-$535KN/AN/AN/AN/AN/AN/A
Financing Cash Flow$914K0.0%$3.8M$5.6M-$10K$914KN/AN/AN/A

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

LIXT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LIXT quarterly financial ratios
MetricQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Return on Equity-25.0%+36.2pp-27.0%+47.6pp-40.3%+31.8pp-119.1%-74.1pp-61.2%-30.1pp-74.7%-72.1%-51.4pp-45.0%+17.0pp
Return on Assets-18.3%+28.6pp-20.5%+33.4pp-36.4%+21.7pp-65.3%-27.4pp-46.9%-19.8pp-53.9%-58.1%-38.7pp-37.9%+16.0pp
Current Ratio2.783.88+0.3x10.42+5.3x1.84-4.5xN/A3.60-10.1x5.13-11.7x6.33-1.4x
Liabilities-to-Equity0.21-0.1x0.18-0.2x0.11-0.1x0.82+0.6x0.31+0.2x0.38+0.3x0.24+0.2x0.190.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Lixte Biotechnology Holdings, Inc. LIXT FY2025 N/A -$6.1M N/A N/A —
Enovix Corporation ENVX FY2025 $31.8M -$156.7M N/A $248.6M 67/100
Lightbridge Corp. LTBR FY2025 $0 -$19.6M N/A $125.4M —
NeoVolta Inc. NEOV FY2026 $13.3M -$21.5M N/A $121.2M 43/100
Bloom Energy Corporation BE FY2025 $2.0B -$88.4M -4.4% $42.1B 52/100
Acuity Inc. AYI FY2026 $4.6B $531.3M 11.5% $9.2B 73/100

Frequently Asked Questions

No, Lixte Biotechnology Holdings, Inc. (LIXT) reported a net loss of $7.4M over the trailing 12 months to March 31, 2026. In fiscal year 2025 it reported a net loss of $6.1M.

Lixte Biotechnology Holdings, Inc. (LIXT) reported diluted earnings per share of -$1.26 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lixte Biotechnology Holdings, Inc. (LIXT) has a return on equity of -62.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Lixte Biotechnology Holdings, Inc. (LIXT) recorded an outflow of $3.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Lixte Biotechnology Holdings, Inc. (LIXT) had $12.7M in total assets as of fiscal year 2025, including both current and long-term assets.

Lixte Biotechnology Holdings, Inc. (LIXT) invested $255K in research and development during fiscal year 2025.

Lixte Biotechnology Holdings, Inc. (LIXT) had 9M shares outstanding as of fiscal year 2025.

Lixte Biotechnology Holdings, Inc. (LIXT) had a current ratio of 3.88 as of fiscal year 2025, which is generally considered healthy.

Lixte Biotechnology Holdings, Inc. (LIXT) had a liabilities-to-equity ratio of 0.18 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Lixte Biotechnology Holdings, Inc. (LIXT) had a return on assets of -47.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2025, Lixte Biotechnology Holdings, Inc. (LIXT) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.1M over that year. Dividing the one by the other, the reported balance equals about 20 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Lixte Biotechnology Holdings, Inc. (LIXT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Lixte Biotechnology Holdings, Inc. (LIXT) reported a net loss of $6.1M while operations used $3.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Lixte Biotechnology Holdings, Inc. (LIXT) reported an operating loss of $5.1M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top